15/05/2019 17:16:00

Transaction in Own Shares

BlackRock Greater Europe Investment Trust Plc - Transaction in Own Shares

PR Newswire

15 May 2019

BlackRock Greater Europe Investment Trust plc (“the Company”)

LEI - 5493003R8FJ6I76ZUW55


Transaction in own shares: purchase of own shares to be held in treasury

The Company announces that it has today purchased 50,000 of its Ordinary Shares at an average price of 349.00 pence per share to be held in treasury.

Following settlement of this purchase on 17 May 2019 the issued share capital of the Company will be 84,968,101 Ordinary Shares, excluding 25,360,837 which are held in treasury.  Shares held in treasury do not carry any voting rights; 23.0% of the Company’s total issued share capital (110,328,938 Ordinary Shares, including treasury shares) will be held in treasury following settlement.

For reporting purposes under the FCA's Disclosure Guidance and Transparency Rules the market should exclude any shares held in treasury and should use the figure of 84,968,101 following settlement when determining if they are required to notify their interest in, or a change to their interest in the Company.


All enquiries:

Caroline Driscoll

Company Secretary

BlackRock Investment Management (UK) Limited

Tel: 0207 743 2427


Related content
11:18 - 
Net Asset Value(s)
21 Jun - 
Net Asset Value(s)
21 Jun - 
Total Voting Rights

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Regulatory news

11:18 E:BRGE
21 Jun E:BRGE
21 Jun E:BRGE
20 Jun E:BRGE
19 Jun E:BRGE
18 Jun E:BRGE
18 Jun E:BRGE
17 Jun E:BRGE


EuroInvestor: In Focus


EuroInvestor: In Focus


EuroInvestor: In Focus

Most read news

  • 24 hours
  • 48 hours
  • 1 week
OSE Immunotherapeutics Will Participate in HealthTech Investor Days (HTID)
Global Arena Holding Inc. (GAHC), Files First Quarter 10Q, and Updates Shareholders on Subsidiaries
Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Eros International Plc (NYSE: EROS) and Encourages Eros Investors to Contact the Firm
Hofseth Biocare ASA: Signed Letter of Intent with Garden of Life® for exclusive use of CollaGo® and ProGo® in the US market
Final Data Analysis of Phase 2 PBC Trial Shows that Genkyotex’s Anti-fibrotic Candidate GKT831 Demonstrated Statistically Significant Improvements in GGT and ALP Over Full Treatment Period

Related stock quotes

Latest news

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
24 June 2019 23:29:31
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190527.1 - EUROWEB7 - 2019-06-25 00:29:31 - 2019-06-24 23:29:31 - 1000 - Website: OKAY